Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using blastomyces dermatitidis surface protein BAD-1

Sarah M. Richer, Melinda L. Smedema, Michelle M. Durkin, T. Tristan Brandhorst, Chadi Hage, Patricia A. Connolly, Diane S. Leland, Thomas Davis, Bruce S. Klein, L. Joseph Wheat

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Serologic tests for antibodies to Blastomyces dermatitidis are not thought to be useful for the diagnosis of blastomycosis, in part due to the low sensitivity of immunodiffusion and complement fixation. Earlier studies have shown that the enzyme immunoassay improves the sensitivity of antibody detection for the diagnosis of blastomycosis. Microplates coated with the B. dermatitidis surface protein BAD-1 were used for testing sera from patients with proven blastomycosis or histoplasmosis and controls. Semi-quantification was accomplished by using standards containing human anti-B. dermatitidis antibodies. The antibodies were detected in 87.8% of the patients with blastomycosis by the enzyme immunoassay compared to 15.0% by immunodiffusion. The specificities were 99.2% for patients with nonfungal infections and healthy subjects and 94.0% for patients with histoplasmosis. The results were highly reproducible on repeat testing. When combined with antigen testing, antibody testing improved the sensitivity from 87.8% to 97.6%. Enzyme immunoassay detection of antibodies against BAD-1 is highly specific, has greatly improved sensitivity over immunodiffusion, and may identify cases with negative results by antigen testing. This assay has the potential to aid in the diagnosis of blastomycosis.

Original languageEnglish
Pages (from-to)143-146
Number of pages4
JournalClinical and Vaccine Immunology
Volume21
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Blastomyces
Blastomycosis
Immunoenzyme Techniques
Membrane Proteins
Antibodies
Immunodiffusion
Enzymes
Testing
Histoplasmosis
Antigens
Serologic Tests
Assays
Healthy Volunteers
Infection
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using blastomyces dermatitidis surface protein BAD-1. / Richer, Sarah M.; Smedema, Melinda L.; Durkin, Michelle M.; Brandhorst, T. Tristan; Hage, Chadi; Connolly, Patricia A.; Leland, Diane S.; Davis, Thomas; Klein, Bruce S.; Wheat, L. Joseph.

In: Clinical and Vaccine Immunology, Vol. 21, No. 2, 02.2014, p. 143-146.

Research output: Contribution to journalArticle

Richer, Sarah M. ; Smedema, Melinda L. ; Durkin, Michelle M. ; Brandhorst, T. Tristan ; Hage, Chadi ; Connolly, Patricia A. ; Leland, Diane S. ; Davis, Thomas ; Klein, Bruce S. ; Wheat, L. Joseph. / Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using blastomyces dermatitidis surface protein BAD-1. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 2. pp. 143-146.
@article{988b31afa08949fcb3aa2fceb14d35fc,
title = "Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using blastomyces dermatitidis surface protein BAD-1",
abstract = "Serologic tests for antibodies to Blastomyces dermatitidis are not thought to be useful for the diagnosis of blastomycosis, in part due to the low sensitivity of immunodiffusion and complement fixation. Earlier studies have shown that the enzyme immunoassay improves the sensitivity of antibody detection for the diagnosis of blastomycosis. Microplates coated with the B. dermatitidis surface protein BAD-1 were used for testing sera from patients with proven blastomycosis or histoplasmosis and controls. Semi-quantification was accomplished by using standards containing human anti-B. dermatitidis antibodies. The antibodies were detected in 87.8{\%} of the patients with blastomycosis by the enzyme immunoassay compared to 15.0{\%} by immunodiffusion. The specificities were 99.2{\%} for patients with nonfungal infections and healthy subjects and 94.0{\%} for patients with histoplasmosis. The results were highly reproducible on repeat testing. When combined with antigen testing, antibody testing improved the sensitivity from 87.8{\%} to 97.6{\%}. Enzyme immunoassay detection of antibodies against BAD-1 is highly specific, has greatly improved sensitivity over immunodiffusion, and may identify cases with negative results by antigen testing. This assay has the potential to aid in the diagnosis of blastomycosis.",
author = "Richer, {Sarah M.} and Smedema, {Melinda L.} and Durkin, {Michelle M.} and Brandhorst, {T. Tristan} and Chadi Hage and Connolly, {Patricia A.} and Leland, {Diane S.} and Thomas Davis and Klein, {Bruce S.} and Wheat, {L. Joseph}",
year = "2014",
month = "2",
doi = "10.1128/CVI.00597-13",
language = "English",
volume = "21",
pages = "143--146",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using blastomyces dermatitidis surface protein BAD-1

AU - Richer, Sarah M.

AU - Smedema, Melinda L.

AU - Durkin, Michelle M.

AU - Brandhorst, T. Tristan

AU - Hage, Chadi

AU - Connolly, Patricia A.

AU - Leland, Diane S.

AU - Davis, Thomas

AU - Klein, Bruce S.

AU - Wheat, L. Joseph

PY - 2014/2

Y1 - 2014/2

N2 - Serologic tests for antibodies to Blastomyces dermatitidis are not thought to be useful for the diagnosis of blastomycosis, in part due to the low sensitivity of immunodiffusion and complement fixation. Earlier studies have shown that the enzyme immunoassay improves the sensitivity of antibody detection for the diagnosis of blastomycosis. Microplates coated with the B. dermatitidis surface protein BAD-1 were used for testing sera from patients with proven blastomycosis or histoplasmosis and controls. Semi-quantification was accomplished by using standards containing human anti-B. dermatitidis antibodies. The antibodies were detected in 87.8% of the patients with blastomycosis by the enzyme immunoassay compared to 15.0% by immunodiffusion. The specificities were 99.2% for patients with nonfungal infections and healthy subjects and 94.0% for patients with histoplasmosis. The results were highly reproducible on repeat testing. When combined with antigen testing, antibody testing improved the sensitivity from 87.8% to 97.6%. Enzyme immunoassay detection of antibodies against BAD-1 is highly specific, has greatly improved sensitivity over immunodiffusion, and may identify cases with negative results by antigen testing. This assay has the potential to aid in the diagnosis of blastomycosis.

AB - Serologic tests for antibodies to Blastomyces dermatitidis are not thought to be useful for the diagnosis of blastomycosis, in part due to the low sensitivity of immunodiffusion and complement fixation. Earlier studies have shown that the enzyme immunoassay improves the sensitivity of antibody detection for the diagnosis of blastomycosis. Microplates coated with the B. dermatitidis surface protein BAD-1 were used for testing sera from patients with proven blastomycosis or histoplasmosis and controls. Semi-quantification was accomplished by using standards containing human anti-B. dermatitidis antibodies. The antibodies were detected in 87.8% of the patients with blastomycosis by the enzyme immunoassay compared to 15.0% by immunodiffusion. The specificities were 99.2% for patients with nonfungal infections and healthy subjects and 94.0% for patients with histoplasmosis. The results were highly reproducible on repeat testing. When combined with antigen testing, antibody testing improved the sensitivity from 87.8% to 97.6%. Enzyme immunoassay detection of antibodies against BAD-1 is highly specific, has greatly improved sensitivity over immunodiffusion, and may identify cases with negative results by antigen testing. This assay has the potential to aid in the diagnosis of blastomycosis.

UR - http://www.scopus.com/inward/record.url?scp=84893252541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893252541&partnerID=8YFLogxK

U2 - 10.1128/CVI.00597-13

DO - 10.1128/CVI.00597-13

M3 - Article

C2 - 24285817

AN - SCOPUS:84893252541

VL - 21

SP - 143

EP - 146

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 2

ER -